Mutant of 3-ketosteroid-delta1-dehydrogenase, recombinant expression vector, recombinant engineering bacterium and application of 3-ketosteroid-delta1-dehydrogenase

By replacing the amino acid sequence of 3-sterone-Δ1-dehydrogenase with specific sites, mutants with high catalytic activity and high thermal stability were obtained, and combined with recombinant expression vectors and engineered bacteria, the enzyme activity and the enzyme in the prior art were solved. The problem of insufficient thermal stability has significantly improved the efficiency and efficiency of industrial production.

CN118879652APending Publication Date: 2024-11-01HUBEI GONGTONG STEROID DRUG RESEARCH INSTITUTE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411059400.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-03
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The existing 3-sterone-Δ1-dehydrogenase is insufficient in industrial applications, resulting in low substrate addition, high enzyme usage, long conversion time and low conversion efficiency.

Method used

By replacing amino acids at specific sites on the amino acid sequence of 3-sterone-Δ1-dehydrogenase, mutants with high catalytic activity and high temperature resistance are obtained, and combined with the application of recombinant expression vectors and engineered bacteria, the expression and stability of enzymes are improved. sex.

Benefits of technology

The catalytic activity of mutants M1 and M2 was increased by 221.2% and 393.9%, the semi-inactivation temperature was increased by 11.8°C and 14.0°C, and the half-life was increased by 6.9 times and 4.2 times, which significantly improved the substrate conversion rate and enzyme dosage efficiency. It is suitable for Industrialized production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879652A_ABST
    Figure CN118879652A_ABST
Patent Text Reader

Abstract

The invention provides a mutant of 3-ketosteroid-delta1-dehydrogenase, a recombinant expression vector, recombinant engineering bacteria and application thereof, and relates to the technical field of enzyme engineering. The mutant comprises a mutant M1 of which the amino acid sequence is as shown in SEQ ID NO.2 and a mutant M2 of which the amino acid sequence is as shown in SEQ ID NO.3. The recombinant expression vector comprises the coding gene of the mutant M1 or the coding gene of the mutant M2. The mutant M1 and the mutant M2 of the 1, 3-ketosteroid-delta1-dehydrogenase have higher substrate addition amount, lower enzyme dosage and higher conversion efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of enzyme engineering technology, and in particular to a mutant of 3-sterol-Δ1-dehydrogenase, a recombinant expression vector, a recombinant engineering bacterium and applications thereof. Background Art

[0002] 3-Sterone-Δ1-dehydrogenase (KsdD) is a key enzyme in the microbial metabolism of steroid compounds, responsible for catalyzing the dehydrogenation reaction of the C1,2 position on the A ring of 3-keto steroid compounds. After the double bond is introduced into the C1,2 position of the A ring of the steroid compound, its anti-inflammatory activity increases exponentially. For example, the anti-inflammatory activity of prednisone acetate generated by the C1,2 dehydrogenation reaction of cortisone acetate increases by 3-4 times. At present, the production process of many important steroid compounds in clinical practice involves the steroid C1,2 dehydrogenation reaction of microorganisms. Therefore, the steroid C1,2 dehydrogenation reaction is the most valuable reaction for the industrial production of prednisone acetate and its homologues, and is a typical representative of the industrial production of steroid drugs by microbial transformation.

[0003] At present, there are still problems such as low enzyme expression in wild strains and low activity expression in recombinant strains during the research process. In terms of industrial application, there are problems such as low substrate addition, high enzyme dosage, long conversion time, and low conversion efficiency. In order to achieve low-cost industrial application of protein 3-sterol-Δ1-dehydrogenase, high activity and high thermal stability are crucial.

[0004] The Chinese patent with publication number CN118207174A discloses a 3-sterone-Δ 1 -dehydrogenase mutants and engineered bacteria and their construction methods and applications. In this patent, 3-sterone-Δ 1 -dehydrogenase amino acid sequence in the mutation site to replace the amino acid residues, to obtain a 3-sterone-Δ 1 -dehydrogenase mutants, but their catalytic activity and heat resistance still need to be improved.

[0005] It should be noted that the information disclosed in the above background technology section is only used to enhance the understanding of the background of the present disclosure, and therefore may include information that does not constitute the prior art known to ordinary technicians in the field. Summary of the invention

[0006] The purpose of the present disclosure is to overcome the deficiencies of the above-mentioned prior art and provide a mutant of 3-sterone-Δ1-dehydrogenase, a recombinant expression vector, a recombinant engineered bacterium and applications thereof, and obtain a mutant of 3-sterone-Δ1-dehydrogenase with high catalytic activity and good high temperature resistance by replacing amino acids at the mutation site of 3-sterone-Δ1-dehydrogenase, so that the recombinant engineered bacterium with the 3-sterone-Δ1-dehydrogenase mutant can prepare steroid drugs more efficiently.

[0007] According to the first aspect of the present disclosure, a mutant of 3-sterol-Δ1-dehydrogenase is provided, wherein the mutant is obtained by mutating the 255th and 311th amino acids of the amino acid sequence of the wild-type 3-sterol-Δ1-dehydrogenase;

[0008] Alternatively, the 311th and 324th amino acids are mutated.

[0009] On the basis of the above technical scheme, preferably, the mutant of 3-sterol-Δ1-dehydrogenase is a mutant M1 in which the glutamic acid at position 255 of the amino acid sequence of the wild-type 3-sterol-Δ1-dehydrogenase is mutated to asparagine, and the threonine at position 311 is mutated to alanine;

[0010] The amino acid sequence of the mutant M1 is shown in SEQ ID NO.2.

[0011] On the basis of the above technical scheme, preferably, the mutant of 3-sterol-Δ1-dehydrogenase is a mutant M2 in which the threonine at position 311 of the amino acid sequence of wild-type 3-sterol-Δ1-dehydrogenase is mutated to alanine, and the threonine at position 324 is mutated to alanine;

[0012] The amino acid sequence of the mutant M2 is shown in SEQ ID NO.3.

[0013] According to a second aspect of the present disclosure, a recombinant expression vector is provided, comprising a gene encoding the mutant M1 or a gene encoding the mutant M2.

[0014] On the basis of the above technical solution, preferably, the coding gene of the mutant M1 is amplified by a specific primer pair; the specific primer pair E225N-F / R and T311A-F / R are respectively:

[0015] E225N-F TGGCGCAATACCACCCTGGTTGAACTGGTGACCGAAGGCG;

[0016] E225N-R TCAACCAGGGTGGTATTGCGCCAAATCGGAATGCCTGCACGCA;

[0017] T311A-F GATCAGGCCTGGTGGTTTCCGGCCGTGGCACCGCTGC;

[0018] T311A-R GCCGGAAAACCACCAGGCCTGATCCATCAGGGTCAGTTCGGC.

[0019] On the basis of the above technical solution, preferably, the coding gene of the mutant M2 is amplified by a specific primer pair; the specific primer pair T311A-F / R and T324A-F / R are respectively:

[0020] T311A-F GATCAGGCCTGGTGGTTTCCGGCCGTGGCACCGCTGC;

[0021] T311A-R GCCGGAAACCACCAGGCCTGATCCATCAGGGTCAGTTCGGC;

[0022] T324A-F GTGGTGCACCTCAGGTTCTGCTGGCAGAACGCAGCCTGCC;

[0023] T324A-R AGCAGAACCTGAGGTGCACCACCCGGCAGCGGTGCCACG.

[0024] On the basis of the above technical solutions, preferably, the recombinant expression vector is a plasmid, phage or virus vector containing a mutant M1 encoding gene or a mutant M2 encoding gene.

[0025] More preferably, the recombinant expression vector is a pET28a plasmid;

[0026] The pET28a plasmid includes a SUMO fusion protein tag and a mutant M1 encoding gene;

[0027] Alternatively, the pET28a plasmid includes a SUMO fusion protein tag and a mutant M2 encoding gene.

[0028] According to a third aspect of the present disclosure, a recombinant engineered bacterium expressing the mutant M1 or mutant M2 is provided, characterized in that the recombinant engineered bacterium is obtained by transfecting the recombinant expression vector into a host bacterium.

[0029] Based on the above technical solution, preferably, the host bacteria is Escherichia coli BL21.

[0030] According to a fourth aspect of the present disclosure, there is provided use of the above-mentioned recombinant engineered bacteria in the preparation of steroid drugs.

[0031] Beneficial effects: The present invention modifies the amino acid sequence of 3-sterone-Δ1-dehydrogenase to obtain mutant M1 with mutation sites E225N and T311A, and mutant M2 with mutation sites T311A and T324A. Compared with the wild type, mutant M1 and mutant M2 both have higher catalytic activity and higher thermal stability. In this way, when the recombinant engineered bacteria with mutant M1 or mutant M2 are used industrially, the amount of substrate added can be increased, while the amount of enzyme used can be reduced, thereby improving the conversion rate of the substrate.

[0032] The specific enzyme activity of mutant M1 was increased to 221.2% compared with the wild type, the catalytic efficiency (kcat / Km) was increased to 168.4%, the half-inactivation temperature was increased by 11.8℃, and the half-life at 30℃ was 21.5 hours, which was 6.9 times higher than that of the wild type. The specific enzyme activity of mutant M2 was increased to 393.9% compared with the wild type, the catalytic efficiency (kcat / Km) was increased to 401.6%, the half-inactivation temperature was increased by 14.0℃, and the half-life at 30℃ was 12.9 hours, which was 4.2 times higher than that of WT. Both mutants showed higher substrate addition concentration, lower enzyme dosage and faster conversion efficiency in the industrial production of cortisone acetate (CA) to prednisone acetate (PA), laying the foundation for its industrial application.

[0033] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The accompanying drawings herein are incorporated into the specification and constitute a part of the specification, illustrate embodiments consistent with the present disclosure, and together with the specification are used to explain the principles of the present disclosure. Obviously, the accompanying drawings described below are only some embodiments of the present disclosure, and for ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without creative work.

[0035] Figure 1 This is a schematic diagram of the half-inactivation temperature results of the wild-type KsdD5 enzyme, the mutant M1 KsdD5 enzyme and the mutant M2 KsdD5 enzyme in one embodiment of the present disclosure.

[0036] Figure 2 This is a schematic diagram of the half-life results of the wild-type KsdD5 enzyme, the mutant M1 KsdD5 enzyme and the mutant M2 KsdD5 enzyme in one embodiment of the present disclosure.

[0037] Figure 3 This is a graph showing the enzyme kinetics Michaelis equation fitting curves of the wild-type KsdD5 enzyme, the mutant M1 KsdD5 enzyme and the mutant M2 KsdD5 enzyme in one embodiment of the present disclosure.

[0038] Figure 4 The HPLC conversion diagram of the mutant M1 KsdD5 enzyme in one embodiment of the present disclosure.

[0039] Figure 5 This is an enzyme conversion HPLC diagram of the mutant M2 type KsdD5 enzyme in one embodiment of the present disclosure. DETAILED DESCRIPTION

[0040] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0041] The disclosed embodiment provides a mutant of 3-sterone-Δ1-dehydrogenase, wherein the mutant of the 3-sterone-Δ1-dehydrogenase is combined with point mutations at positions 255, 311 and 324 of the amino acid sequence of the wild-type 3-sterone-Δ1-dehydrogenase to obtain two mutants with high catalytic activity and good high temperature resistance. The two mutants are obtained by mutating the amino acids at positions 255 and 311 of the amino acid sequence of the wild-type 3-sterone-Δ1-dehydrogenase, or by mutating the amino acids at positions 311 and 324.

[0042] The disclosed embodiment provides a mutant of 3-sterone-Δ1-dehydrogenase, which is a mutant M1 in which the glutamic acid at position 255 of 3-sterone-Δ1-dehydrogenase is mutated to asparagine, and the threonine at position 311 is mutated to alanine. That is, the mutant M1 is obtained by point mutation of the 255th and 311th positions of the amino acid sequence of the wild-type 3-sterone-Δ1-dehydrogenase.

[0043] The disclosed embodiment provides a mutant of 3-sterone-Δ1-dehydrogenase, wherein the mutant is a mutant M2 in which the threonine at position 311 of the 3-sterone-Δ1-dehydrogenase is mutated to alanine, and the threonine at position 324 is mutated to alanine. That is, the mutant M2 is obtained by point mutation of the 311th and 324th positions of the amino acid sequence of the wild-type 3-sterone-Δ1-dehydrogenase.

[0044] An embodiment of the present disclosure provides a recombinant expression vector, which includes a gene encoding a mutant M1 or a gene encoding a mutant M2.

[0045] Exemplarily, the coding gene of the mutant M1 is amplified by a specific primer pair; the specific primer pair E225N-F / R and T311A-F / R are respectively:

[0046] E225N-F (SEQ ID NO.4):

[0047] TGGCGCAATAACCACCCTGGTTGAACTGGTGACCGAAGGCG;

[0048] E225N-R (SEQ ID NO.5):

[0049] TCAACCAGGGTGGTATTGCGCCAAATCGGAATGCCTGCACGCA;

[0050] T311A-F (SEQ ID NO.6):

[0051] GATCAGGCCTGGTGGTTTCCGGCCGTGGCACCGCTGC;

[0052] T311A-R (SEQ ID NO. 7):

[0053] GCCGGAAACCACCAGGCCTGATCCATCAGGGTCAGTTCGGC. The specific primer pair is a point mutation primer that has been subjected to point mutation treatment.

[0054] Exemplarily, the coding gene of the mutant M2 is amplified by a specific primer pair; the specific primer pair T311A-F / R and T324A-F / R are respectively:

[0055] T311A-F (SEQ ID NO.6):

[0056] GATCAGGCCTGGTGGTTTCCGGCCGTGGCACCGCTGC;

[0057] T311A-R (SEQ ID NO. 7):

[0058] GCCGGAAACCACCAGGCCTGATCCATCAGGGTCAGTTCGGC;

[0059] T324A-F (SEQ ID NO. 8):

[0060] GTGGTGCACCTCAGGTTCTGCTGGCAGAACGCAGCCTGCC;

[0061] T324A-R (SEQ ID NO.9):

[0062] AGCAGAACCTGAGGTGCACCACCCGGCAGCGGTGCCACG. The specific primer pair is a point mutation primer that has been subjected to point mutation treatment.

[0063] In some embodiments, the recombinant expression vector is a plasmid, phage or viral vector containing a mutant M1 encoding gene or a mutant M2 encoding gene. For example, the recombinant expression vector is a pET28a plasmid. The pET28a plasmid includes a SUMO fusion protein tag and a mutant M1 encoding gene; or, the pET28a plasmid includes a SUMO fusion protein tag and a mutant M2 encoding gene.

[0064] The disclosed embodiment provides a recombinant engineered bacterium that can express mutant M1 and mutant M2. The recombinant engineered bacterium can be obtained by transfecting the above-mentioned recombinant expression vector into a host bacterium. For example, the mutant M1 encoding gene is transfected into Escherichia coli BL21 through a pET28a plasmid with a SUMO fusion protein tag to obtain a recombinant engineered bacterium that can express mutant M1. The recombinant engineered bacterium can be used in actual industrial production to transform substrates to obtain steroid drugs.

[0065] The present disclosure is further described below in conjunction with specific examples. In the following examples, the culture medium formula used is:

[0066] LB solid medium: yeast extract powder 5g / L, tryptone 10g / L, sodium chloride 10g / L, agar powder 20g / L.

[0067] LB liquid medium: yeast extract powder 5 g / L, tryptone 10 g / L, sodium chloride 10 g / L.

[0068] Example 1. Screening of mutants

[0069] Step 1: homology modeling of 3-sterol-Δ1-dehydrogenase is performed, and molecular dynamics simulation optimization is performed to obtain the protein monomer of 3-sterol-Δ1-dehydrogenase.

[0070] Step 2: Integrate a combined strategy of computer-assisted screening, structural analysis and experimental verification to obtain target amino acid sequences SEQ ID NO. 2 and SEQ ID NO. 3 with high thermal stability and high catalytic activity.

[0071] Step 3, after PCR amplification of E225N-F / R and T311A-F / R using site-directed mutagenesis primers, homologous recombination with the vector after enzyme cutting was performed by homologous recombination technology, and then transformed into Escherichia coli DH5α to obtain mutant M1 positive clones. After PCR amplification of T311A-F / R and T324A-F / R using site-directed mutagenesis primers, homologous recombination with the vector after enzyme cutting was performed by homologous recombination technology, and then transformed into Escherichia coli DH5α to obtain mutant M2 positive clones. The mutant M1 is a wild-type 3-sterone-Δ1-dehydrogenase amino acid sequence (as shown in SEQ ID NO.1), in which the glutamic acid at position 255 is mutated to asparagine, and at the same time, the threonine at position 311 is mutated to alanine. The mutant M2 is a wild-type 3-sterol-Δ1-dehydrogenase amino acid sequence (as shown in SEQ ID NO.1), wherein the threonine at position 311 is mutated to alanine, and the threonine at position 324 is mutated to alanine.

[0072] The PCR amplification procedure includes: (1) pre-denaturation at 98°C for 3 min; (2) cycles: including 30 cycles, each cycle including 98°C for 10 s, 65°C for 5 s and 72°C for 1-3 min; (3) termination.

[0073] After PCR amplification in step 3, the specific steps are as follows: the PCR reaction mixture is digested with DpnI to remove the template, and then the PCR reaction product is purified and recovered. After the wild-type plasmid is double digested with BamHI and XholI, the empty fragment is recovered. The PCR reaction product and the plasmid fragment after digestion are connected with homologous recombinase and transformed into Escherichia coli DH5α to obtain positive clones. The positive clones include positive clones corresponding to mutant M1 and mutant M2, respectively. The specific primer sequences used in PCR are shown in Table 1.

[0074] Table 1. PCR primer sequences

[0075] Primer name Primer sequences E225N-F TGGCGCAATAACCACCCTGGTTGAACTGGTGACCGAAGGCG E225N-R TCAACCAGGGTGGTATTGCGCCAAATCGGAATGCCTGCACGCA T311A-F GATCAGGCCTGGTGGTTTCCGGCCGTGGCACCGCTGC T311A-R GCCGGAAACCACCAGGCCTGATCCATCAGGGTCAGTTCGGC T324A-F GTGGTGCACCTCAGGTTCTGCTGGCAGAACGCAGCCTGCC T324A-R AGCAGAACCTGAGGTGCACCACCCGGCAGCGGTGCCACG

[0076] Example 2: Mutant expression

[0077] Plasmids were extracted from the mutant M1 positive clone and mutant M2 positive clone constructed in Example 1, and the plasmids were transformed into competent Escherichia coli BL21 to obtain mutant M1 positive strains and mutant M2 positive strains, respectively, and the positive strains can express the corresponding 3-sterol-Δ1-dehydrogenase mutants. Specifically:

[0078] Step S1, the plasmids extracted from the mutant M1 positive clone and the mutant M2 positive clone were transformed into competent Escherichia coli BL21, respectively, spread on LB solid culture medium, and cultured at 37°C for 12h to obtain single colonies of the mutant M1 positive strain and single colonies of the mutant M2 positive strain, respectively.

[0079] Step S2, seed culture: a single colony of the mutant M1 positive strain was inoculated into a 500 ml shaking flask filled with 20% LB liquid culture medium, and cultured at 37° C. and 220 rpm for 8-10 h to obtain mutant M1 seed solution.

[0080] The same culture method as in step S2 was used to obtain the mutant M2 seed solution.

[0081] Step S3, expression culture: The mutant M1 seed solution was inoculated with 5% of the inoculum into a 2000ml shake flask filled with LB liquid medium (containing 50 μg / ml kanamycin) and cultured at 37°C, 220 rpm for 3-4 hours until the bacterial solution OD 600 When the value was 0.6-0.8, IPTG with a final concentration of 0.42 mmol / L was added to induce expression for 18-20 hours and then centrifuged to obtain mutant M1 recombinant bacteria.

[0082] The mutant M2 recombinant bacteria were obtained by the same culture method as in step S3.

[0083] Preparation of crude enzyme solution: The recombinant bacteria obtained in step S3 are suspended in Tris-HCl buffer, ultrasonically disrupted, and centrifuged to obtain the supernatant to obtain the crude enzyme solution.

[0084] Preparation of pure enzyme solution: The crude enzyme solution was subjected to nickel column affinity chromatography to obtain the pure enzyme solution of the corresponding mutant.

[0085] The mutant M1 recombinant bacteria can obtain the crude enzyme solution and pure enzyme solution of the mutant M1 type 3-sterol-Δ1-dehydrogenase; the mutant M2 recombinant bacteria can obtain the crude enzyme solution and pure enzyme solution of the mutant M2 type 3-sterol-Δ1-dehydrogenase.

[0086] Example 3: Enzyme activity test

[0087] 3-sterone-Δ1-dehydrogenase activity assay method: The activity of the purified enzyme was determined at 25°C using a colorimetric method. The reaction mixture (3 mL) contained 50 mM Tris-HCl (pH 7.0), 1.5 mM phenazine methyl sulfate (PMS), 40 μM 2,6-dichlorophenol indoxyl (DCPIP), 25 μM flavin adenine dinucleotide (FAD), test enzymes (including wild-type 3-sterone-Δ1-dehydrogenase, mutant M1 type 3-sterone-Δ1-dehydrogenase, mutant M2 type 3-sterone-Δ1-dehydrogenase), and 500 μM MCA (dissolved in methanol). The decrease in absorbance at 600 nm (ε600 = 18.7 × 103 cm-1 M-1) was monitored on a UV spectrophotometer every 10 seconds for 2 minutes. The protein concentration was determined using the Bradford method. One unit (U) of enzyme activity is defined as the amount of enzyme that reduces 1 μM DCPIP per minute. Specific enzyme activity is expressed as micromoles per minute per milligram (U / mg).

[0088] Protein separation and purification: Mutant M1 recombinant bacteria and mutant M2 recombinant bacteria were resuspended in Tris buffer (50mMTris, 100mMNaCl, 5mM imidazole, 5% glycerol, pH7.5, 25°C). The suspension was sonicated on ice (total time 30 minutes, power 35%, sonication 3 seconds, interval 3 seconds), and the lysate was centrifuged at 10,000×g for 15 minutes at 4°C to obtain the crude enzyme solution of mutant M1 type 3-sterone-Δ1-dehydrogenase and the crude enzyme solution of mutant M2 type 3-sterone-Δ1-dehydrogenase. The crude enzyme solution was applied to Ni-NTA column for protein purification, and the bound protein was eluted with imidazole gradient to obtain the pure enzyme solution of mutant M1 type 3-sterone-Δ1-dehydrogenase and the pure enzyme solution of mutant M2 type 3-sterone-Δ1-dehydrogenase. The collected eluate was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then subjected to enzyme activity assay.

[0089] After purification, the wild-type (WT) 3-sterone-Δ1-dehydrogenase, mutant M1 type 3-sterone-Δ1-dehydrogenase and mutant M2 type 3-sterone-Δ1-dehydrogenase were respectively subjected to relative enzyme activity determination. The results are shown in Table 2. The relative enzyme activity of the wild-type KsdD enzyme is 3.3U / mg, the relative enzyme activity of the mutant M1 type 3-sterone-Δ1-dehydrogenase is 7.3U / mg, which is 221.2% higher than that of the WT type, and the relative enzyme activity of the mutant M2 type 3-sterone-Δ1-dehydrogenase is 13.0, which is 393.9% higher than that of the WT type.

[0090] Table 2. Enzyme activity assay results

[0091] Serial number Mutant / wild type Specific enzyme activity (U / mg) 1 KsdD5-WT 3.3 2 M1(E225N-T311A) 7.3 3 M2(T311A-T324A) 13.0

[0092] Example 4. Thermal stability and half-life

[0093] (1) Half-inactivation temperature determination: Incubate the wild-type 3-sterol-Δ1-dehydrogenase solution, the mutant M1 3-sterol-Δ1-dehydrogenase solution, and the mutant M2 3-sterol-Δ1-dehydrogenase solution (100 μg / mL) at various temperatures (25°C, 30°C, 35°C, 40°C, 45°C, and 50°C) for 15 minutes. The enzyme here can be a purified enzyme or a crude enzyme. Then measure the residual activity at 25°C, and the highest activity is set as 100%. Figure 1 As shown in Table 3, the half-inactivation temperature of the wild-type 3-sterone-Δ1-dehydrogenase is 32.9°C, the half-inactivation temperature of the mutant M1 type 3-sterone-Δ1-dehydrogenase is 44.7 hours, and the half-inactivation temperature of the mutant M2 type 3-sterone-Δ1-dehydrogenase is 46.9 hours. Compared with the wild-type 3-sterone-Δ1-dehydrogenase, the half-inactivation temperatures of the mutant M1 type 3-sterone-Δ1-dehydrogenase and the mutant M2 type 3-sterone-Δ1-dehydrogenase increased by 11.8°C and 14.0°C, respectively.

[0094] (2) Half-life determination: The wild-type 3-sterol-Δ1-dehydrogenase solution, the mutant M1 3-sterol-Δ1-dehydrogenase solution, and the mutant M2 3-sterol-Δ1-dehydrogenase solution (100 μg / mL) were incubated at 30°C for different time periods. The residual enzyme activity was measured at 25°C, and the initial enzyme activity was set as 100%. Figure 2 As shown in Table 3, the half-life of the wild-type 3-sterone-Δ1-dehydrogenase is 3.1 hours, the half-life of the mutant M1 type 3-sterone-Δ1-dehydrogenase is 21.5 hours, and the half-life of the mutant M2 type 3-sterone-Δ1-dehydrogenase is 12.9 hours. Compared with the wild-type 3-sterone-Δ1-dehydrogenase, the half-lives of the mutant M1 type 3-sterone-Δ1-dehydrogenase and the mutant M2 type 3-sterone-Δ1-dehydrogenase were increased by 6.9 times and 4.2 times, respectively.

[0095] Table 3. Half-inactivation temperature and half-life measurement results

[0096]

[0097] Example 5: Analysis of Enzymatic Properties

[0098] The kinetic parameters of wild-type 3-sterol-Δ1-dehydrogenase, mutant M1 3-sterol-Δ1-dehydrogenase and mutant M2 3-sterol-Δ1-dehydrogenase were measured using different concentrations of cortisone acetate.

[0099] Reagents used: different concentrations of cortisone acetate (0.01mM, 0.05mM, 0.1mM, 0.2mM, 0.4mM, 0.8mM, 1.2mM), Tris-HCl buffer (50mM, pH7, 3mL), purified enzyme of wild-type 3-sterol-Δ1-dehydrogenase, purified enzyme of mutant M1 type 3-sterol-Δ1-dehydrogenase, and purified enzyme of mutant M2 type 3-sterol-Δ1-dehydrogenase.

[0100] 200 μg of wild-type 3-sterol-Δ1-dehydrogenase, 200 μg of mutant M1 3-sterol-Δ1-dehydrogenase, and 200 μg of mutant M2 3-sterol-Δ1-dehydrogenase were mixed with different concentrations of substrate cortisone acetate (CA) in Tris-HCl buffer, reacted at 25°C, and measured using a UV spectrophotometer. cat / K m It combines the catalytic reaction rate and substrate affinity of the enzyme and is an important parameter for measuring the catalytic efficiency of the enzyme. cat is the catalytic constant, also called the conversion number, k cat The larger the value, the higher the catalytic efficiency of the enzyme; m Refers to the substrate concentration at which the reaction rate reaches 1 / 2 of the maximum rate.

[0101] like Figure 3 and Table 4 with wild-type 3-sterol-Δ1-dehydrogenase (k cat / K m The value is 120.63min -1 ·mmol -1 Compared with the mutant M1 type 3-sterol-Δ1-dehydrogenase, the k cat / K m The value is 203.123min -1 ·mmol -1 L, k of mutant M2 3-sterol-Δ1-dehydrogenase cat / K m The value is 461.63min -1 ·mmol -1 ·L, which are significantly higher than the wild-type 3-sterol-Δ1-dehydrogenase (KsdD5-WT). Compared with the wild-type 3-sterol-Δ1-dehydrogenase, they increased by 168.3% and 401.6%, respectively, indicating that the overall catalytic performance of these two 3-sterol-Δ1-dehydrogenase mutants has been significantly improved.

[0102] Table 4 shows the enzyme kinetic parameters of wild-type KsdD5 enzyme and its mutants M1 and M2

[0103]

[0104] Example 6, Enzymatic Conversion Efficiency

[0105] A 100 mL reaction system simulating industrial conversion of cortisone acetate (CA) was constructed to compare the actual conversion efficiency of the two mutants and the wild-type KsdD5 enzyme. The conversion system included 4 g CA, 1 g bacterial sludge (wild-type KsdD5 enzyme, mutant M1 KsdD5 enzyme, mutant M2 KsdD5 enzyme), appropriate amounts of isopropanol and PMS.

[0106] The conversion reaction was carried out at 30°C and measured by high performance liquid chromatography (HPLC). Figure 4 and Figure 5 As shown. The maximum conversion rate of the wild-type KsdD5 enzyme is only 55%, while the maximum conversion rate of the mutant M2 KsdD5 enzyme is 94%; the mutant M1 KsdD5 enzyme shows a higher initial conversion rate slope, and the maximum conversion efficiency is 95%, which is close to the maximum conversion rate of the mutant M2 KsdD5 enzyme. Therefore, the mutant M1 KsdD5 enzyme and the mutant M2 KsdD5 enzyme use lower enzyme amounts in the industrial conversion system and have higher conversion efficiency.

[0107] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A mutant of 3-sterol-Δ1-dehydrogenase, characterized in that: The mutant is obtained by mutating the 255th and 311th amino acids of the amino acid sequence of the wild-type 3-sterol-Δ1-dehydrogenase; Alternatively, the 311th and 324th amino acids are mutated.

2. The mutant of 3-sterol-Δ1-dehydrogenase according to claim 1, characterized in that: The mutant is a mutant M1 in which the glutamic acid at position 255 of the amino acid sequence of the wild-type 3-sterol-Δ1-dehydrogenase is mutated to asparagine, and the threonine at position 311 is mutated to alanine; The amino acid sequence of the mutant M1 is shown in SEQ ID NO.

2.

3. The mutant of 3-sterol-Δ1-dehydrogenase according to claim 1, characterized in that: The mutant is a mutant M2 in which the threonine at position 311 of the amino acid sequence of the wild-type 3-sterol-Δ1-dehydrogenase is mutated to alanine, and the threonine at position 324 is mutated to alanine; The amino acid sequence of the mutant M2 is shown in SEQ ID NO.

3.

4. A recombinant expression vector, characterized in that: It includes the gene encoding the mutant M1 according to claim 2, or the gene encoding the mutant M2 according to claim 3.

5. The recombinant expression vector according to claim 4, characterized in that: The coding gene of the mutant M1 was amplified by a specific primer pair; the specific primer pair E225N-F / R and T311A-F / R were: E225N-F TGGCGCAATAACCACCCTGGTTGAACTGGTGACCGAAGGCG; E225N-R TCAACCAGGGTGGTATTGCGCCAAATCGGAATGCCTGCACGCA; T311A-F GATCAGGCCTGGTGGTTTCCGGCCGTGGCACCGCTGC; T311A-R GCCGGAAACCACCAGGCCTGATCCATCAGGGTCAGTTCGGC; The coding gene of the mutant M2 was amplified by a specific primer pair; the specific primer pairs T311A-F / R and T324A-F / R were: T311A-F GATCAGGCCTGGTGGTTTCCGGCCGTGGCACCGCTGC; T311A-R GCCGGAAACCACCAGGCCTGATCCATCAGGGTCAGTTCGGC; T324A-F GTGGTGCACCTCAGGTTCTGCTGGCAGAACGCAGCCTGCC; T324A-R AGCAGAACCTGAGGTGCACCACCCGGCAGCGGTGCCACG.

6. The recombinant expression vector according to any one of claims 4 to 5, characterized in that: The recombinant expression vector is a plasmid, phage or virus vector containing a mutant M1 encoding gene or a mutant M2 encoding gene.

7. The recombinant expression vector according to claim 6, characterized in that: The recombinant expression vector is a pET28a plasmid; The pET28a plasmid includes a SUMO fusion protein tag and a mutant M1 encoding gene; Alternatively, the pET28a plasmid includes a SUMO fusion protein tag and a mutant M2 encoding gene.

8. A recombinant engineered bacterium expressing the mutant of 3-sterol-Δ1-dehydrogenase according to claim 2 or 3, characterized in that: The recombinant engineered bacteria are obtained by transfecting the recombinant expression vector according to any one of claims 4 to 7 into host bacteria.

9. The recombinant engineered bacterium according to claim 8, characterized in that The host bacteria is Escherichia coli BL21.

10. Use of the recombinant engineered bacteria according to claim 8 or 9 in the preparation of steroid drugs.